9H-fluoren-9-one O-isopropyloxime | 1233087-09-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 9H-fluoren-9-one O-isopropyloxime
• 英文别名: N-propan-2-yloxyfluoren-9-imine
• CAS: 1233087-09-6
• 化学式: C₁₆H₁₅NO
• 分子量: 237.301
• InChiKey: GNZHVQZPFUQXKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  21.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  9-芴酮肟 、 异丙醇 在 四氯化碳 、 四丁基碘化铵 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三苯基膦 作用下， 以 乙腈 为溶剂， 反应 8.0h， 以56%的产率得到9H-fluoren-9-one O-isopropyloxime
  参考文献：
  名称：

  使用三苯基膦/四氯化碳从醇高效一锅合成肟醚

  摘要：

  描述了在三氯化碳中使用三苯基膦方便有效地从醇中进行肟的一锅O-烷基化。在这种方法中，在回流的乙腈中，在催化量的碘化四丁铵存在下，用三苯基膦，四氯化碳，肟和DBU的混合物处理醇，可以高收率提供相应的O-烷基醚。该方法是用各种结构多样的醇对肟进行高效的O-烷基化。对于不对称肟醚的半经验量子力学计算（AM1）表明Z异构体的形成热较低。 肟-醇-O-烷基化-三苯基膦-四氯化碳-DBU

  DOI：

  10.1055/s-0029-1218711

文献信息

• N-FUNCTIONALIZED AMIDES AS HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Niu Deqiang

  公开号：US20080267917A1

  公开（公告）日：2008-10-30

  The present invention relates to functionalized amides of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及式I或式II的功能化酰胺，包括抑制丝氨酸蛋白酶活性的药用可接受盐、酯或前药，尤其是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也用作抗病毒剂。本发明进一步涉及包含上述化合物的药物组合物，用于给患有HCV感染的对象进行给药。本发明还涉及通过管理包含本发明化合物的药物组合物来治疗对象中的HCV感染的方法。
• OXYIMINO COMPOUNDS AND THE USE THEREOF
  申请人：Masui Moriyasu

  公开号：US20100240703A1

  公开（公告）日：2010-09-23

  The invention relates to oxyimino compounds of (Formula I), and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein: Y is CO or SO m ; Z is hydrogen, each optionally substituted lower alkyl, lower alkenyl, aryl, heterocyclyl etc. R 1 and R 2 are each independently hydrogen, each optionally substituted lower alkyl, lower alkenyl, cycloalkyl, aryl, heterocyclyl etc., each X is independently ═O, optionally substituted lower alkyl, cyano, nitro etc., m is 1 or 2, p is O, 1 or 2 and q is O or 1. The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

  本发明涉及公式I的氧亚胺化合物及其药学上可接受的盐、前药和溶剂化合物，其中：Y为CO或SOm；Z为氢、每个可选择的取代较低的烷基、较低的烯基、芳香基、杂环基等。R1和R2分别独立地为氢、每个可选择的取代较低的烷基、较低的烯基、环烷基、芳香基、杂环基等，每个X独立地为═O、可选择的取代较低的烷基、氰基、硝基等，m为1或2，p为O、1或2，q为O或1。本发明还涉及使用公式I的化合物来治疗、预防或缓解对钙通道阻滞有反应的疾病，特别是N型钙通道。本发明的化合物特别适用于治疗疼痛。
• CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Gai Yonghua

  公开号：US20080267916A1

  公开（公告）日：2008-10-30

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及式I的化合物，或其药学上可接受的盐、酯或前药，其抑制丝氨酸蛋白酶活性，特别是丝氨酸蛋白酶NS3-NS4A的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也有用作抗病毒剂。本发明还涉及包含上述化合物的制药组合物，用于治疗患有丙型肝炎感染的受试者。本发明还涉及通过给予包含本发明化合物的制药组合物来治疗受试者的丙型肝炎感染的方法。
• MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
  申请人：Sun Ying

  公开号：US20070281885A1

  公开（公告）日：2007-12-06

  The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
  申请人：Sun Ying

  公开号：US20080125444A1

  公开（公告）日：2008-05-29

  The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.